INTS

3.9601

1.00% -0.0399

Dopo l'orario di chiusura: 3.95 -0.0101 -0.26%

Intensity Therapeutics Inc (INTS)

Panoramica Notizia Cronologia dei prezzi Financials Perché INTS Giù? Forum Previsione

Precedente Chiudi:

$4.00

Aprire:

$4.01

Volume 24 ore:

38,668

Relative Volume:

0.97

Capitalizzazione di mercato:

$10.70M

Reddito:

Utile/perdita netta:

$-10.69M

Rapporto P/E:

-0.5592

EPS:

-7.0818

Flusso di cassa netto:

$-9.07M

1 W Prestazione:

-4.81%

1M Prestazione:

-18.68%

6M Prestazione:

-36.69%

1 anno Prestazione:

-46.93%

Intervallo 1D:

$3.9008

$4.19

Intervallo di 1 settimana:

$3.9008

$4.35

Portata 52W:

$3.51

$43.50

Intensity Therapeutics Inc Stock (INTS) Company Profile

Nome

Intensity Therapeutics Inc

Settore

Healthcare (1080)

Industria

Biotechnology (604)

Telefono

203-221-7381

Indirizzo

1 ENTERPRISE DRIVE, SUITE 430, SHELTON

Dipendente

Cinguettio

Prossima data di guadagno

2026-08-06

Ultimi documenti SEC

INTS's Discussions on Twitter

Compare INTS vs VRTX, REGN, ARGX, RVMD, ONC

Azioni	Prezzo	Cap. di mercato	Reddito	Reddito netto	Flusso di cassa	EPS
INTS Intensity Therapeutics Inc	3.9601	11.24M	0	-10.69M	-9.07M	-7.0818
VRTX Vertex Pharmaceuticals Inc	505.75	133.25B	12.34B	4.34B	3.71B	16.87
REGN Regeneron Pharmaceuticals Inc	803.48	82.16B	14.92B	4.42B	3.79B	41.04
ARGX Argen X Se Adr	851.29	54.80B	4.16B	1.29B	734.26M	19.58
RVMD Revolution Medicines Inc	203.71	43.99B	742.00K	-1.37B	-1.07B	-7.0731
ONC Beone Medicines Ltd Adr	347.48	40.62B	5.76B	514.49M	1.10B	4.4813

Intensity Therapeutics Inc Borsa (INTS) Ultime notizie

Aug 12, 2026

INTS: Q2 2026 saw higher R&D spend, resumed trial enrollment, and strong early TNBC efficacy data - TradingView

Aug 11, 2026

Transcript : Intensity Therapeutics, Inc., Q2 2026 Earnings Call, Aug 11, 2026 - marketscreener.com

Aug 11, 2026

Form 8K Intensity Therapeutics Inc For: 11 August By Investing.com - Investing.com Australia

Aug 11, 2026

INTS: Net loss rose 19% to $3M as clinical trials resumed, with $9.5M cash and $30M more needed for completion - TradingView

Aug 11, 2026

Earnings call transcript: Intensity Therapeutics misses Q2 2026 EPS as shares slip premarket - Investing.com

Aug 11, 2026

Intensity Therapeutics (INTS) Advances Clinical Trials Amidst Ch - GuruFocus

Aug 11, 2026

Intensity Therapeutics Reports $3.0 Million Q2 Net Loss - Quiver Quantitative

Aug 11, 2026

Intensity Therapeutics reports Q2 2026 net loss of $3.0M, cash $9.5M; resumes select trial enrollment - TradingView

Aug 11, 2026

Intensity Therapeutics Q2 net loss widens as R&D costs rise - TradingView

Aug 11, 2026

INTS: Resumed clinical trial enrollment and raised capital, with improved early TNBC study results - TradingView

Aug 11, 2026

BRIEF-Intensity Therapeutics Q2 Operating Income USD -3.084 Million - TradingView

Aug 11, 2026

Intensity Therapeutics Reports Second Quarter 2026 Financial Results and Provides Business Update - PR Newswire

Aug 11, 2026

INTENSITY THERAPEUTICS, INC. Q2 2026: Net income $(3.0M), EPS $(1.11) — 10-Q Summary - TradingView

Aug 11, 2026

Aug 10, 2026

INTS Q2'26 Earnings: EPS estimate is (0.87) USD - TradingView

Aug 10, 2026

Aug 09, 2026

BRIEF-Intensity Therapeutics Q1 Operating Income USD -2.526 Million - TradingView

Aug 09, 2026

Aug 07, 2026

Intensity Therapeutics (INTS.US) will release its earnings report on August 11. - Moomoo

Aug 07, 2026